Literature DB >> 29791797

Modulating Macrophage Polarization through CCR2 Inhibition and Multivalent Engagement.

Michael B Deci1, Scott W Ferguson1, Sydney L Scatigno1, Juliane Nguyen1.   

Abstract

Excessive or prolonged recruitment of inflammatory monocytes to damaged tissue can significantly worsen patient outcomes. Monocytes migrate to sites of tissue inflammation in response to high local concentrations of CCL2, a chemokine that binds to and signals through the CCR2 receptor. While the role of CCR2 in cellular migration is well studied, it is unclear how CCR2 inhibition affects macrophage polarization and if multivalency can increase downstream signaling effects. Using affinity selection with a phage library, we identified a novel single-chain variable fragment (scFv) (58C) that binds specifically and with high affinity to the N-terminal domain of CCR2 ( KD = 59.8 nM). The newly identified 58C-scFv bound to native CCR2 expressed on macrophages and MDA-MB-231 cells, inhibited migration, and induced a pro-inflammatory M1-phenotype in macrophages. The M1/M2 macrophage phenotype ratio for monomeric 58C-scFv was significantly increased over the negative control by 1.0 × 104-fold (iNOS/Arg-1), 5.1 × 104-fold (iNOS/Mgl2), 3.4 × 105-fold (IL-6/Arg-1), and 1.7 × 106-fold (IL-6/Mgl2). The multivalent display of 58C-scFv on liposomes further reduced migration of both cell types by 25-40% and enhanced M1 polarization by 200% over monomeric 58C-scFv. These studies demonstrate that CCR2 inhibition polarizes macrophages toward an inflammatory M1 phenotype, and that multivalent engagement of CCR2 increases the effects of 58C-scFv on polarization and migration. These data provide important insights into the role of multivalency in modulating binding, downstream signaling, and cellular fate.

Entities:  

Keywords:  cellular migration; chemokine receptors; multivalency; phenotype switching; scFv

Mesh:

Substances:

Year:  2018        PMID: 29791797      PMCID: PMC6499372          DOI: 10.1021/acs.molpharmaceut.8b00237

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  57 in total

1.  Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte chemotaxis.

Authors:  Yuya Terashima; Nobuyuki Onai; Masako Murai; Masahiko Enomoto; Vongsakorn Poonpiriya; Tsuyoshi Hamada; Kazushi Motomura; Makiko Suwa; Taichi Ezaki; Tatsuya Haga; Shiro Kanegasaki; Kouji Matsushima
Journal:  Nat Immunol       Date:  2005-07-03       Impact factor: 25.606

Review 2.  Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.

Authors:  John Condeelis; Jeffrey W Pollard
Journal:  Cell       Date:  2006-01-27       Impact factor: 41.582

3.  Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.

Authors:  Liang Xu; Cheng-Cheng Huang; Weiqun Huang; Wen-Hua Tang; Antonina Rait; Yu Zhi Yin; Idalia Cruz; Lai-Man Xiang; Kathleen F Pirollo; Esther H Chang
Journal:  Mol Cancer Ther       Date:  2002-03       Impact factor: 6.261

Review 4.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.

Authors:  Alberto Mantovani; Silvano Sozzani; Massimo Locati; Paola Allavena; Antonio Sica
Journal:  Trends Immunol       Date:  2002-11       Impact factor: 16.687

5.  Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation.

Authors:  Geert Raes; Lea Brys; Bhola K Dahal; Jef Brandt; Johan Grooten; Frank Brombacher; Guido Vanham; Wim Noël; Pieter Bogaert; Tom Boonefaes; Anne Kindt; Rafaël Van den Bergh; Pieter J M Leenen; Patrick De Baetselier; Gholamreza Hassanzadeh Ghassabeh
Journal:  J Leukoc Biol       Date:  2004-12-09       Impact factor: 4.962

6.  Role of the first extracellular loop in the functional activation of CCR2. The first extracellular loop contains distinct domains necessary for both agonist binding and transmembrane signaling.

Authors:  K H Han; S R Green; R K Tangirala; S Tanaka; O Quehenberger
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

7.  Recombinant human antibody single chain variable fragments reactive with Candida albicans surface antigens.

Authors:  C G Haidaris; J Malone; L A Sherrill; J M Bliss; A A Gaspari; R A Insel; M A Sullivan
Journal:  J Immunol Methods       Date:  2001-11-01       Impact factor: 2.303

8.  Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences.

Authors:  Robert D Stout; Chuancang Jiang; Bharati Matta; Illya Tietzel; Stephanie K Watkins; Jill Suttles
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

9.  Multiple activation steps of the N-formyl peptide receptor.

Authors:  E R Prossnitz; T L Gilbert; S Chiang; J J Campbell; S Qin; W Newman; L A Sklar; R D Ye
Journal:  Biochemistry       Date:  1999-02-23       Impact factor: 3.162

10.  Macrophage activation: classical versus alternative.

Authors:  Andrea Classen; Jorge Lloberas; Antonio Celada
Journal:  Methods Mol Biol       Date:  2009
View more
  14 in total

1.  miR-511-3p protects against cockroach allergen-induced lung inflammation by antagonizing CCL2.

Authors:  Danh C Do; Jie Mu; Xia Ke; Karan Sachdeva; Zili Qin; Mei Wan; Faoud T Ishmael; Peisong Gao
Journal:  JCI Insight       Date:  2019-10-17

2.  MiR-101a loaded extracellular nanovesicles as bioactive carriers for cardiac repair.

Authors:  Jinli Wang; Christine J Lee; Michael B Deci; Natalie Jasiewicz; Anjali Verma; John M Canty; Juliane Nguyen
Journal:  Nanomedicine       Date:  2020-04-08       Impact factor: 5.307

3.  Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.

Authors:  Sulaiman S Alhudaithi; Rashed M Almuqbil; Hanming Zhang; Elizabeth R Bielski; Wei Du; Fatemah S Sunbul; Paula D Bos; Sandro R P da Rocha
Journal:  Mol Pharm       Date:  2020-11-10       Impact factor: 4.939

4.  Reduction of Real-Time Imaging of M1 Macrophage Chemotaxis toward Damaged Muscle Cells is PI3K-Dependent.

Authors:  Hiromi Yano; Masataka Uchida; Tatsuya Saito; Takafumi Aoki; Michael J Kremenik; Eri Oyanagi
Journal:  Antioxidants (Basel)       Date:  2018-10-08

5.  Effect of CCR2 inhibitor-loaded lipid micelles on inflammatory cell migration and cardiac function after myocardial infarction.

Authors:  Jinli Wang; Min Jeong Seo; Michael B Deci; Brian R Weil; John M Canty; Juliane Nguyen
Journal:  Int J Nanomedicine       Date:  2018-10-15

6.  The CCR2/MCP-1 Chemokine Pathway and Lung Adenocarcinoma.

Authors:  Payal Mittal; Liqing Wang; Tatiana Akimova; Craig A Leach; Jose C Clemente; Matthew R Sender; Yao Chen; Brandon J Turunen; Wayne W Hancock
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639

7.  Carrier-Free CXCR4-Targeted Nanoplexes Designed for Polarizing Macrophages to Suppress Tumor Growth.

Authors:  Michael B Deci; Maixian Liu; Jacqueline Gonya; Christine J Lee; Tingyi Li; Scott W Ferguson; Emily E Bonacquisti; Jinli Wang; Juliane Nguyen
Journal:  Cell Mol Bioeng       Date:  2019-08-27       Impact factor: 2.321

8.  Boosting the Biogenesis and Secretion of Mesenchymal Stem Cell-Derived Exosomes.

Authors:  Jinli Wang; Emily E Bonacquisti; Adam D Brown; Juliane Nguyen
Journal:  Cells       Date:  2020-03-09       Impact factor: 6.600

9.  Uric Acid Has Direct Proinflammatory Effects on Human Macrophages by Increasing Proinflammatory Mediators and Bacterial Phagocytosis Probably via URAT1.

Authors:  Camilo P Martínez-Reyes; Aarón N Manjarrez-Reyna; Lucia A Méndez-García; José A Aguayo-Guerrero; Beatriz Aguirre-Sierra; Rafael Villalobos-Molina; Yolanda López-Vidal; Karen Bobadilla; Galileo Escobedo
Journal:  Biomolecules       Date:  2020-04-09

Review 10.  Mechanism of mesenchymal stem cells in spinal cord injury repair through macrophage polarization.

Authors:  Nan An; Jiaxu Yang; Hequn Wang; Shengfeng Sun; Hao Wu; Lisha Li; Meiying Li
Journal:  Cell Biosci       Date:  2021-02-23       Impact factor: 7.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.